Decision-making by healthcare payers

Respiratory Medicine

Volumn 96, Issue SUPPL. 3, 2002, Pages

  Levine, M ^a   Taylor, R ^b   Ryan, M ^c   Sculpher, M ^d  

^a CENTRE FOR EVALUATION OF MEDICINES   (Canada)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c ST JAMES S HOSPITAL   (Ireland)

^d UNIVERSITY OF YORK   (United Kingdom)

Author keywords

Chronic obstructive pulmonary disease; Cost effectiveness; Decision models; Healthcare payers; QALYs; Utility

Indexed keywords

BUDGET; CONFERENCE PAPER; HEALTH CARE; HEALTH CARE SYSTEM; HUMAN; MEDICAL DECISION MAKING; MEDICAL INFORMATION; MEDICAL PRACTICE; PRIORITY JOURNAL; RESOURCE MANAGEMENT; CHRONIC OBSTRUCTIVE LUNG DISEASE; COST BENEFIT ANALYSIS; DECISION MAKING; ECONOMICS; HEALTH CARE COST; HEALTH CARE ORGANIZATION; HEALTH PERSONNEL ATTITUDE; METHODOLOGY; REIMBURSEMENT; REVIEW; TREATMENT OUTCOME;

ATTITUDE OF HEALTH PERSONNEL; COST-BENEFIT ANALYSIS; DECISION MAKING; HEALTH CARE COSTS; HEALTH CARE RATIONING; HUMANS; INSURANCE, HEALTH, REIMBURSEMENT; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TREATMENT OUTCOME;

EID: 0036674379     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0954-6111(02)80032-4     Document Type: Conference Paper

References (22)

1. Taylor R. Using health outcomes data to inform decision-making. Government agency perspective. Pharmacoeconomics 2001; 19 (Suppl 2): 33-38.
2. Lancry P-J, O'Connor R, Stempel D, Raz M. Using health outcomes data to inform decision-making. Healthcare payer perspective. Pharmacoeconomics 2001; 19 (Suppl 2): 39-47.
3. Panzarino PJ Jr, Nash DB. Cost-effective treatment of depression with selective serotonin reuptake inhibitors. Am J Manag Care 2001; 7: 173-184.
4. Mapel D, Pearson M. Obtaining evidence for use by healthcare payers on the success of chronic obstructive pulmonary disease management. Respir Med 2002; 96 (Suppl C): S23-S30.
5. Hill SR, Mitchell AS, Henry DA. Problems with the interpretation of pharamacoeconomic analyses: a review of submissions to the Australian Pharmaceutical Benefits Scheme. JAMA 2000; 28: 2116-2121.
6. Anis AH, Rahman T, Schechter MT. Using pharmacoeconomic analysis to make drug insurance coverage decisions. Pharmacoeconomics 1998; 13: 119-126.
7. Feeny D, Furlong W, Torrance GW. The Health Utilities Index: an update. Quality of Life Newsletter No. 22. Mapi Research Institute, 1999.
8. Kind P. The EuroQoL instrument: an index of health-related quality of life. In: Spilker B. Quality of Life and Pharmacoeconomics in Clinical Trials. Philadelphia: Lippincott-Raven, 1996.
9. Dolan P, Gudex C, Kind P, Williams A. A Social Tariff for EuroQoL: Results from a UK General Population Survey. Centre for Health Economics Discussion Paper 138. Centre for Health Economics, University of York: CHE, 1995.
10. Raftery J. NICE: faster access to modern treatments? Analysis of guidance on health technologies. Br Med J 2001; 323: 1300-1303.
11. http://www.ispor.org/workpaper/healthscience/TFModeling.pdf
12. Consensus conference on economic modelling in health technology assessment, Sheffield, England, April 22-23, 1999. Pharmacoeconomics 2000; 17: 443-513.
13. Price M, Briggs A. The development of an economic model to assess the cost-effectiveness of asthma management strategies. Pharmacoeconomics (in press).
14. Financial and statistical analysis of claims and payments - 1993. General Medical Services (Payment) Board, 1994
15. Financial and statistical analysis of claims and payments - 2000. General Medical Services (Payment) Board, 2001
16. Report for the year ended 31st December 2000, General Medical Services (Payment) Board, 2001
17. www.cso.ie/publications/demog/popmig.pdf
18. Walley T, Murphy M, Codd M, Johnson Z, Quirke T. Effects of a monetary incentive on primary care prescribing in Ireland: changes in prescribing patterns in one health board 1990-1995. Pharmacoepidemiol Drug Saf 2000; 9: 591-598.
19. Barry M, Heerey A, Feely J. Drug reimbursement in Ireland. IMJ 2000; 93: 71-72.
20. National Centre for Pharmacoeconomics. Pharmacoeconomic review on pharmaceutical expenditure in Ireland 1993-2000 & Pricing and reimbursement strategies in Europe. Report for the Department of Health & Children, 2000.
21. Barry M, Heerey A, McCulloch D, Ryan M, Merry C, Hughes C, Feely J. The Irish National Centre for Pharmacoeconomics: its rationale and role. IMJ 1999; 92: 337-339.
22. National Centre for Pharmacoeconomics. Irish Healthcare Technology Assessment. Guidelines. Under review by the Department of Health & Children, 2000.